References
- WeissmanMMBlandRCCaninoGJCross national epidemiology of major depression and bipolar disorderJAMA1996272932998656541
- LépineJPGastparMMendlewiczJTyleeADepression in the community: the first pan-European study DEPRES (Depression Research in European Society)Int Clin Psychopharmacol199711929
- MurrayCJLLopezAThe Global Burden of Disease (volume I in The Global Burden of Disease and Injury Series) Harvard University Press Boston, MA, USA1996
- GuzeSBRobinsESuicide and primary affective disordersBr J Psychiatry19701174374385481206
- Le PapeALecomteTPrévalence et prise en charge médicale de la dépressionFrance 1996–1997. CREDES Paris1999
- MachadoMIskedjianMRuizIEinarsonTRRemission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trialsCurr Med Res Opin2006221825183716968586
- StahlSMGradyMMMoretCBrileyMSNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressantsCNS Spectr20051073274716142213
- AnsseauMVon FrenckellRGérardMAInterest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamineEur Neuropsychopharmacol199111131211821700
- HayashiMMimuraMOtsuboTKamijimaKEffect of high-dose milnacipran in patients with depressionNeuropsychiatr Dis Treat2007369970219300602
- OkumuraKFurukawaTARemission rates with milnacipran 100 mg/day and 150 mg/day in the long term treatment of major depressionClin Drug Invest200626135142
- ClauwDJMeasePPalmerRHGendreauRMWangYMilnacipran treatment for fibromyalgia syndrome: one-year durability of responseNeurology200870suppl 1A162 (abstract)
- MeasePJClauwDJGendreauRMThe efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trialJ Rheumatology200936112
- LecrubierYWeillerEHerguetaTMINI Mini International Neuropsychiatric Interview. French version 5.0.0Hôpital de la Pitié Salpétrière, INSERM, Paris;1998
- MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry197913382389444788
- GuyWClinical Global ImpressionsECDEU Assessment Manual for PsychopharmacologyPublication ADM No. 76–338National Institute of Mental Health Rockville, MD, USA1976
- MontgomerySABaldwinDSBlierPWhich antidepressants have demonstrated superior efficacy? A review of the evidenceInt Clin Psychopharmacol20072232332917917550
- BauerMTharmanathanPVolzHPMoellerHJFreemantleNThe effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysisEur Arch Psychiatry Clin Neurosci200925917218519165525
- KasperSEveryday problems in treating depression: focus on SNRIsCNS Spectr2008137 Suppl 114518622367
- SteenADen BoerJAA double-blind six months comparative study of milnacipran and clomipramine in major depressive disorderInt Clin Psychopharmacol19971252692819466161
- DeakinJFWDoes selectivity matter?Int Clin Psychopharmacol199611Suppl 113178732439
- MöllerHJVolzHPDrug treatment of depression in the 1990s: an overview of achievements and future possibilitiesDrugs1996526256389118813
- OliéJPGourionDMontagneARostinMPoirierMFMilnacipran et venlafaxine à posologie flexible (jusqu’à 200 mg/j) dans le traitement ambulatoire des épisodes dépressifs majeurs modérés à sévères de l’adulte: étude exploratoire de 24 semaines, randomisée en double insuEncephale20093559560420004291